Coupled with its clinical efficacy and tolerability, studies have shown that using levofloxacin in CAP is associated with reduced days in hospital, and increased cost-effectiveness. A pivotal study by Marrie used a clinical pathway model, in which patients were randomized to receive levofloxacin or other usual standard care. The admission rate was lower for levofloxacin treated patients and those admitted were discharged earlier. These are important economic benefits associated with levofloxacin, making it an extremely valuable cost-effective therapy in CAP.